Rockwell Medical sales skyrockets 20% to $19.1 million
By Brie CarterKey points
- Rockwell Medical (NASDAQ:RMTI) reported third-quarter 2026 net sales of $19.1 million, up 20% from $15.9 million a year earlier.
- Gross profit increased 37% to $3.1 million, while gross margin improved to 16% from 14%; quarterly net loss widened to $2.3 million.
- The proposed combination with Vantive's hemodialysis business is projected by the company to generate annual revenue of $400 million–$450 million.
Rockwell Medical (NASDAQ:RMTI) reported third-quarter 2026 net sales of $19.1 million, up 20% year over year, while its net loss widened to $2.3 million, or $0.59 per share.
Revenue increased from $15.9 million a year earlier, while gross profit rose 37% to $3.1 million and gross margin improved to 16% from 14%.
Adjusted EBITDA recorded a loss of $267,000, compared with income of $50,000 a year earlier, while cash, cash equivalents and available-for-sale investments declined to $22.5 million from $24.8 million at June 30.
For the first nine months of 2026, revenue increased 7% to $54.2 million, gross profit rose 18% to $9.3 million, and net loss widened to $5.1 million from $4.8 million a year earlier.
Separately, Rockwell Medical agreed to acquire Vantive's global hemodialysis business for a $125 million base purchase price, with closing expected in mid-2027, and estimated that the combined business could generate annual revenue of $400 million–$450 million.
Frequently asked questions
More from United States
Spectrum Brands reports $25.8 million fiscal Q4 profit
YETI reports $509.4M in Q3 revenue, up 4%, trims annual forecast
T1 Energy Q3 loss narrows to $41.6 million
Wolverine raises outlook after delivering $505 million Q3 revenue
Dingdong revenue accelerates 10.8% to RMB7.38 billion
Prudential advisory sales reach record $1.4 billion
